

## **C-CAMP inks agreement with Agilent to boost scientific advancements in biopharma**

14 October 2022 | News

### **Catalysing more research and development of biopharmaceuticals in compliance with global regulatory framework in India**

Bengaluru-based Centre for Cellular and Molecular Platform (C-CAMP) has signed an agreement with Agilent Technologies to pave the way for research and technology development in the sector of biosimilars and biopharmaceuticals, a core strength of both the organizations.

This agreement will primarily focus on mass spectrometry-based biotherapeutics/biosimilar characterization, a platform C-CAMP champions with its existing state-of-the-art mass spectrometry facilities across proteomics, metabolomics, lipidomics, glycomics, and biologics research.

Through this partnership, both organizations will leverage each other's capabilities to hold joint training sessions and seminars for researchers across biopharma/ biosimilars startups and established companies.

C-CAMP and Agilent will collaborate on product development and services for the biopharmaceutical industry, using the high-end scientific infrastructures and skill sets that both Agilent and C-CAMP share.

Upon signing the agreement, Dr Taslimarif Saiyed, C-CAMP CEO & Director commented, "C-CAMP is steadily growing in the area of biopharmaceuticals and this partnership will greatly benefit the delivery of deep-science technologies to the biopharma sector. With this MoU, the startups associated with C-CAMP can easily access their high-end mass spectrometry solutions and technologies."